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Abstract Mismatch repair–deficient (dMMR) cancers generate a substantial number of im-
munogenic neoantigens, rendering them sensitive to immunotherapy. Yet, there is consid-
erable variability in responses, and roughly one-half of dMMR cancers are refractory to
immunotherapy. Here we study a patient with dMMR lung cancer refractory to immunother-
apy. The tumor exhibited typical dMMR molecular features, including exceptionally high
frameshift insertions and deletions (indels). Despite the treatment inducing abundant intra-
tumoral T-cell infiltrates, it failed to elicit tumor regression, pointing to the T cells lacking
cytotoxic activity. A post-treatment tumor demonstrated compound heterozygous frame-
shift deletions located upstream of the kinase domain in the gene encoding JAK1 protein,
down-regulation of JAK1 and mediators of its signal transduction, and total loss of JAK1
phosphorylation. Importantly, one of the JAK1 mutations, despite not being detected in
the pretreatment tumor, was found at low variant allele frequency in the pretreatment cir-
culating tumor DNA, suggesting clonal selection of the mutation. To our knowledge, this
report provides the most detailed look yet at defective JAK1 signaling in the context of
dMMR and immunotherapy resistance. Together with observations of JAK1 frameshift
indels being enriched in dMMR compared with MMR-proficient tumors, our findings dem-
onstrate the critical function of JAK1 in immunological surveillance of dMMR cancer.
[Supplemental material is available for this article.]
INTRODUCTION
The mismatch DNA repair (MMR) system corrects errors in base insertion, deletion, or mis-
incorporation that arise during DNA replication and recombination. Tumors with mismatch
repair deficiency (dMMR)—due to germline or acquired deficiency of MMR proteins—repre-
sent ∼2%–4% of all cancers (Dudley et al. 2016). These tumors have exceptionally high num-
bers of somatic mutations (Cancer Genome Atlas Network 2012), especially frameshift
insertion/deletions (indels) that generate a large proportion of mutant neoantigens,
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rendering them more responsive to programmed death-1 (PD-1)- or programmed death-
ligand 1 (PD-L1)-directed therapy (Dudley et al. 2016). Immune checkpoint inhibitors yield
durable tumor responses in 30%–40% of patients with dMMR cancers (Marabelle et al.
2020). Anti PD-1 antibody pembrolizumab is now approved by the United States Food
and Drug Administration (FDA) for treatment of unresectable or metastatic dMMR tumors,
irrespective of histology (Merck Sharp and Dohme 2018). Yet, one-half to two-thirds of
dMMR cancers fail to respond or have disease progression within 6 mo of immunotherapy,
suggesting primary resistance.
Here we report the identification of compound heterozygous Janus kinase 1 (JAK1)mu-
tations in a dMMR cancer that result in functional JAK1 deficiency associated with resistance
to immune checkpoint blockade. Furthermore, detailed analyses of a paired pre- and post-
treatment tumor, circulating tumor DNA (ctDNA), plasma, and peripheral bloodmononucle-
ar cells (PBMCs) reveal dynamic changes in JAK1 allelic burden over time, which is integrally
linked to systemic and tumor immune response dynamics and the patient’s clinical trajectory.
Our findings provide clinical evidence of how highly mutated tumors may grow unimpeded
by immune recognition and have implications for primary resistance to immune checkpoint
blockade in dMMR tumors.
RESULTS
Clinical Course and Mismatch Repair Deficiency
A 64-yr-old female ex-smoker presented to her primary care physician with left-sided chest
and flank pain. Computed tomography (CT) scan revealed multiple pleural nodules, medias-
tinal lymphadenopathy, liver nodules, and a right adrenal mass. Liver biopsy showed small
cells with scant cytoplasm, hyperchromatic nuclei, and inconspicuous nuclei, with extensive
necrosis and mitotic activity. Immunohistochemistry (IHC) for the neuroendocrine markers
chromogranin and synaptophysin was positive. The patient was diagnosed with extensive-
stage small-cell lung cancer (SCLC) and treated with carboplatin and etoposide for six cycles
(Fig. 1A). Although CT imaging during treatment showed a partial response, she developed
progressive disease, with enlarging liver lesions and adrenal lesions soon after completion of
chemotherapy. She then received a topotecan-based investigational drug combination with
no response.
At presentation to our clinic, she was noted to have a personal history of endometrial can-
cer at age 48, and a family history of early-onset colorectal cancers and endometrial cancer
(Fig. 1B). Given the strong family history, which met the Amsterdam II clinical criteria for sus-
pected Lynch syndrome (Vasen et al. 1999), we assessed for evidence of dMMR, revealing
loss of MLH1 protein expression by IHC (Fig. 1C). Follow-up testing demonstrated an MLH1
deleterious germlinemutation (c.1845_1847del, p. K618del; Fig. 1D).Given thedMMR tumor,
she was enrolled on an investigational immunotherapy-combination of PD-L1 inhibitor and
poly(ADP-ribose) polymerase (PARP) inhibitor (Thomas et al. 2019). The trial was designed
based on preclinical observations of DNA damage caused by PARP inhibitors increasing cyto-
solic DNA, which activated the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon
genes (STING) innate immune pathway, ultimately yielding T-cell recruitment and PD-L1 ex-
pression (Sen et al. 2019). CT scan after 4 wk on treatment showed a mixed response, with in-
crease in size of pleural, liver, and adrenal lesions and shrinkage of a right lung hilar mass (Fig.
1E). Given the possibility of immune-related pseudoprogression, and because the patient was
asymptomatic, treatment was continued. She subsequently developed worsening right upper
quadrant pain, nausea, and anorexia. A CT scan 8 wk after treatment showed continued wors-
ening of pleural, hepatic, and right adrenal masses. The right hilar lymph node response was
maintained (Fig. 1E). She was taken off treatment for disease progression and died 2 wk later.
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We sought to investigate the basis of primary resistance to immune checkpoint inhibitor com-
bination in this patient, despite the tumor being dMMR (Fig. 2A).
Tumor Mismatch Repair Deficiency and Immune Response Dynamics
Pretreatment tumor biopsy was obtained from one of liver lesions. First, we performed
whole-exome sequencing (WES) and RNA sequencing (RNA-seq) of the pretreatment tumor.
Consistent with the known loss of MLH1 protein, somatic MLH1 deleterious mutation was
observed, with a significantly lower mutation allele frequency compared with the germline
variant (Fig. 2B). The somatic copy-number landscape showed complete loss of minor allele
of Chromosome 3 and displayed evidence of genomic instability (Supplemental Fig. S1;
Cancer Genome Atlas Network 2012), together indicating MLH1 loss of heterozygosity.
The pretreatment tumor harbored markedly high indel tumor mutational burden (TMB)
(n =129) compared with tumors of 18 other SCLC patients who enrolled on the same clinical
trial (median [95% confidence interval]: 14 indels [9.0–17.4]; Fig. 2C) (Thomas et al. 2019).
Indel TMB in this patient was also higher relative to papillary renal cell carcinoma, a cancer
type with the highest indel TMB across 19 distinct cancers in a previous report (Turajlic et al.
2017). Total TMB was comparable to other SCLCs (Supplemental Fig. S2), although it re-
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Figure 1. Patient clinical course and germline mismatch repair (MMR) deficiency. (A) Patient clinical course,
treatment, response, and timelines. (B) Patient genogram. (C ) Hematoxylin and eosin staining (top) and
MLH1 IHC (bottom). The red arrowhead in the bottom panel indicates loss of MLH1 expression on tumor cells,
whereas the yellow arrowhead indicates intact MLH1 expression in normal hepatic cells. Black bars, 100 µm.
(D) Integrated Genomics Viewer panel of germlineMLH1mutation. (E) Contrast-enhanced computed tomog-
raphy (CT) scans pretreatment (left), 4 wk (middle) after treatment, and 8 wk (right) after treatment. Red arrows,
yellow arrows, orange arrowheads, and light blue arrowheads indicate pleural lesions, right mediastinal lymph
nodes, liver lesions, and right adrenal mass, respectively. (dMMR) Mismatch repair deficiency, (W) week, (PR)
partial response, (PD) progressive disease, (COL) colorectal cancer, (BR) breast cancer, (THY) thyroid cancer,
(UT) endometrial cancer, (H&E) hematoxylin and eosin, (IHC) immunohistochemistry staining, (Ref) reference,
(Alt) alteration.
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dMMR tumor phenotype, mutational signature analysis revealed a high proportion of
dMMR-related signatures (35.3% signature 6 and 15; Fig. 2D; Alexandrov et al. 2020).
Next, we evaluated changes in tumor immune microenvironment in pre- and post-treat-
ment tumors using exome, transcriptome, and IHC. The post-treatment tumor was obtained
2 wk after treatment from the same liver lesion that was biopsied pretreatment. Total and
indel TMB were similar between pre- and post-treatment tumors (Supplemental Fig. S3).
Despite the lack of clinical response, the post-treatment tumor was characterized by mark-
edly high intratumoral and stromal CD8 T-cell infiltrates and high PD-L1 expression. In com-
parison, tumor infiltrating lymphocytes (TILs) were not observed and tumor cells focally
expressed PD-L1 in the pretreatment tumor (Fig. 2E). Consistently, up-regulation of cytotoxic







Figure 2. MLH1 loss in the tumor and induction of cancer immunogenicity with treatment. (A) Schema of tis-
sue sampling and time points. (B) Integrated Genomics Viewer panel of somaticMLH1mutation and mutation
allele frequency in normal (PBMC) and tumor samples. The difference of mutation allele frequency was statisti-
cally evaluated by a χ2 test. (C ) Total number of indels in the present case and 18 other patients with relapsed
small-cell lung cancer enrolled in the clinical trial of durvalumab and olaparib (Thomas et al. 2019). The present
case is indicated by the red circle. (D) Proportion of mutational signatures (Alexandrov et al. 2020) in the pres-
ent case. (E) CD3, CD8, and PD-L1 IHCs in pre- and post-treatment tumors. Scale bars, 100 µm. (F ) Expression
of cytotoxic T-cell genes (top panels) and interferon-related genes (bottom panels) in pre- and post-treatment
tumors. (G) Changes of normalized enrichment scores by single sample gene set enrichment analysis of
immune-related hallmark gene sets between pre- and post-treatment tumors. (H) Changes of plasma interfer-
on-γ and CXCL10 levels at pretreatment, 2 wk and 8 wk after treatment. The y-axes are logarithm-transformed.
(I ) Percentage of activated (Ki67+, HLA-DR+) cells among either CD4+ or CD8+ T cells in PBMCs at pretreat-
ment, 2 wk and 8 wk after treatment. (W) Week, (PBMC) peripheral blood mononuclear cells, (WES)
whole-exome sequencing, (TMB) tumor mutational burden, (indel) insertion/deletion, (dMMR) mismatch re-
pair deficiency, (IHC) immunohistochemistry staining, (TPM) transcripts per million, (PD-L1) programmed-
death ligand-1, (NES) normalized enrichment score, (IFN-γ) interferon-gamma.
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(CCL5, CXCL10, IFITM1, and OASL) were observed in the post-treatment compared with
the pretreatment tumor (Fig. 2F). Further, single sample gene set enrichment analysis also
revealed up-regulation of multiple immune and inflammatory pathways after treatment
(Fig. 2G; Supplemental Table S1).
To evaluate the corresponding changes in systemic immunity, we examined the patient’s
plasma and PBMCs pretreatment, 2 wk (corresponding to the post-treatment biopsy time
point) and 8 wk (at disease progression) after treatment. Interferon-gamma (IFN-γ) and
IFN-associated chemokine CXCL10 were transiently elevated at 2 wk but returned to pre-
treatment levels 8 wk after treatment (Fig. 2H). Similarly, activated (Ki67+ HLA-DR+) CD4+
and CD8+ T cells transiently increased at 2 wk but returned to pretreatment levels by 8 wk
(Fig. 2I; Supplemental Fig. S4). Changes in other cytokines and immune subsets are shown
in Supplemental Figures S5 and S6.
Discovery of Functional Loss of JAK1 Signaling by Compound Heterozygous Mutations
Despite induction of tumor immunity, the dMMR tumor in our patient proved refractory to
immune checkpoint inhibitor combination. To investigate the resistancemechanisms, we ex-
amined WES and RNA-seq of pre- and post-treatment tumors. Given the discordant clinical
response (progression of all lesions except the right hilar lymph node) and because small
core biopsies may often not capture the tumor heterogeneity, we also examined ctDNA
WES-sampled pretreatment.
Tumor cellularity was high in both pre- and post-treatment tumors (Supplemental Fig.
S7). We identified 530 and 539 variants in pre- and post-treatment tumors, respectively.
Consistent with dMMR, frameshift indels were prevalent both before and after treatment
(65 [12.3%] and 64 [11.9%], respectively). Most variants (n=425) were shared between the
two time points (Supplemental Fig. S8; Supplemental Table S2). We discovered a JAK1
frameshift deletion (c.1289delC p. Pro430Argfs∗2) in both pre- and post-treatment tumors
(variant allele frequency [VAF] = 43.8% and 39.7%, respectively) (Table 1; Fig. 3A).
Notably, another JAK1 frameshift deletion (c.2580delA, p. Lys860Asnfs∗16) was found in
the post-treatment tumor (VAF=39.7%) but was not detected in the pretreatment tumor
(Table 1; Fig. 3A,B). Notably, both JAK1 variants were found in the pretreatment ctDNA,
but with low VAF (Pro430Argfs∗2 variant: 0.5%; Lys860Asnfs∗16 variant: 8.6%, respectively).
Both JAK1 variants were located upstream of the kinase domains and likely truncate the pro-
tein or cause nonsense-mediated decay (Fig. 3A). JAK1 Pro430Argfs∗2 and Lys860Asnfs∗16
have previously been reported as recurrent mutations (Fig. 3A), especially in microsatellite
unstable tumors (Albacker et al. 2017), and reported as nonfunctional mutations (Ren
et al. 2013). We also assessed changes in VAF of tumor-derived RB1 mutation in pre- and














mutation ID Genotype Samples
JAK1 Chr 1 NC_000001.10:
g.65325833delG
c.1289del




JAK1 Chr 1 NC_000001.10:
65306997delT
c.2580del
p.P860Nfs Frameshift Deletion COSV61086989 Heterozygous Post-treatment tumor,
pretreatment ctDNA
(JAK1) Janus kinase 1, (COSMIC) Catalogue of Somatic Mutations in Cancer, (ctDNA) circulating tumor DNA.
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post-treatment tumors. The RB1 p.Pro374fs variant decreased in the post-treatment tumor
compared with the pretreatment tumor (77.6% and 63.2% pre- and post-treatment, respec-
tively), suggesting that this major clone did not expand, in contrast to the subclonewith JAK1
composite mutations.
Homozygous JAK1 mutations are notable given reports of immunotherapy resistance
linked to emergence of mutations in the IFN-γ signaling pathway (Zaretsky et al. 2016).
However, JAK1 heterozygous mutations would not carry the same functional significance
as homozygous mutations, as signaling would still occur upon IFN exposure through the
wild-type JAK1 protein from the nonmutated allele. To examinewhether the JAK1mutations
we found were present in different alleles, resulting in a compound heterozygote with likely
loss of function versus two variants on the same allele, with less definitive impact, we exam-
ined the two JAK1 frameshift variants in RNA-seq. Post-treatment tumor RNA-seq showed
only the JAK1 frameshift Pro430Argfs∗2 variant, whereas the other JAK1 Lys860Asnfs∗16
variant was not detected in transcripts (Supplemental Fig. S9), suggesting that the two






Figure 3. Functional loss of signaling by compound heterozygous JAK1mutation. (A) Schematic representa-
tion of JAK1 gene and the two variants observed in pre- and post-treatment tumors. The numbers next to the
COSMIC identifiers indicate the numbers of mutations found in COSMIC (Tate et al. 2019) (https://cancer
.sanger.ac.uk/cosmic/). (B) Integrated Genomics Viewer panels of the JAK1 Lys860Asn∗16 variant in pre-
and post-treatment tumors. (C ) Mutation frequency comparison of JAK1 Lys860Asn∗16 variant between
pre- and post-treatment tumors. (D) Changes in gene expressions of JAK1 and STATs between pre- and
post-treatment tumors. The y-axis shows logarithm 2 transformed fold changes of gene expression between
pre- and post-treatment tumors. (E) Immunohistochemistry stainings (IHCs) of JAK1 (left) and phosphorylated
JAK1 (right) proteins in the post-treatment tumors in the present case (top) and hepatic cells in a healthy donor
(bottom). Scale bars, 100 µm. (JAK1) Janus kinase 1, (COSMIC) Catalogue of Somatic Mutations in Cancer, (W)
weeks, (Ref) reference, (Alt) alteration, (STAT) signal transducers and activators of transcription, (FC) fold
change.
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To assess the impact of the mutations on JAK1 function, we examinedmRNA expression
of JAK1 and downstream signal transducers and activators of transcription (STAT).
Expression of JAK1 itself and most STAT family genes except STAT1 were down-regulated
in the post-treatment compared with the pretreatment tumor (Fig. 3D). Upon activation,
JAKs trans-phosphorylate each other at tyrosines within the kinase domain and phosphory-
late the cytoplasmic tail of the receptor (O’Shea et al. 2015). To further understand the effect
of the mutations on JAK1, we assessed JAK1 and phosphorylated JAK1 protein expression
in the post-treatment tumor. Whereas JAK1 was diffusely expressed on the tumor cells,
phosphorylation of JAK1 was totally absent compared with hepatic cells in a healthy donor
(Fig. 3E). Considering that the composite JAK1mutations are located upstream of the kinase
domain (Fig. 3A), it is likely that they affected the function and downstream signaling of
JAK1, rather than JAK1 protein expression.
DISCUSSION
Patients with dMMR tumors experience highly variable responses, and roughly one-half to
two-thirds are refractory to PD-1/PD-L1-targeted therapies. Understanding the molecular
mechanisms of primary resistance may help identify dMMR tumors that are unlikely to re-
spond to immunotherapy. Here we study a patient with dMMR SCLC and JAK1 compound
heterozygous mutations that were associated with primary resistance to immunotherapy
combination treatment. Loss of JAK1 function has previously been implicated in primary
and acquired immunotherapy resistance in melanoma (Zaretsky et al. 2016), colorectal can-
cer (Grasso et al. 2018), and endometrioid cancer (Gulhan et al. 2020). To our knowledge,
this report provides the most detailed look yet of impaired JAK1 signaling in the context
of immunotherapy-resistant dMMR tumors (Fig. 4). Our findings support the notion that tu-
mors growing out under immune selective pressure likely start out as a heterogeneous mix-
ture, in which sensitive tumor cells are eliminated and resistant tumor cells grow
progressively (Fig. 4).
Mechanisms underlying the substantial diversity among responses of dMMR tumors to
immunotherapy are poorly understood. Mandal et al. (2019) reported that indel mutational
load rather than the burden of missense mutations were associated with the extent of immu-
notherapy response among dMMR tumors. dMMR tumors also display frequent mutations in
immune genes, such as those related to antigen presentation machinery, including biallelic
losses of B2M and HLA genes (Grasso et al. 2018), suggesting that these tumors frequently
undergo immunoediting driven by selection for genetic events allowing immune escape.
Consistently, recent reports have identified nonfunctional genomic alterations of B2M and
JAK1 in dMMR tumors resistant to immune checkpoint blockade (Gurjao et al. 2019;
Gulhan et al. 2020). Indeed, JAK1 frameshift indels including the variants identified in the
present study are found more frequently in dMMR tumors than in MMR-proficient ones
(Albacker et al. 2017; Gulhan et al. 2020). Although several other mechanisms regulating im-
mune response have been proposed in dMMR tumors, none of them have been shown to
impact clinical outcomes to immunotherapy (Supplemental Table S3).
Despite the lack of clinical response, we noted a striking increase in tumor and systemic
immunogenicity 2 wk after treatment, as demonstrated by the marked increases in TILs and
IFN-related gene expression and accompanied by increases in tumor PD-L1 expression,
plasma IFN-γ, and CXCL10, and activated T cells in the peripheral blood. Although a tumor
sample from beyond the 2-wk time point was not available, the blood-based markers point
to the immune response being transient; IFN-γ, CXCL10, and activated T cells returned to
pretreatment levels 8 wk after treatment. Clonal expansion of JAK1-mutated resistant tumor
cells may explain the brief and nonsustained nature of the immune activation. Transient
Genomic and immune responses in IO-resistant dMMR
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immunogenicity may also have resulted from PARP inhibition, given activation of the cGAS
and STING pathways and enhanced IFN-stimulated gene expression observed in preclinical
models following PARP inhibition (Pantelidou et al. 2019; Sen et al. 2019). However, clinical
studies to date suggest that the STING pathway activation may not be a dominant effect of
PARP inhibition in patients (Lampert et al. 2020).
The present study had several limitations. First, we did not observe genomic alterations
in genes with known roles in immune evasion (e.g., STK11 and LKB1) or antigen presentation
(e.g., B2M, TAP1, TAP2, andHLA) in tumors or ctDNA. However, other underlying resistance
mechanisms cannot be excluded (Supplemental Table S3). Although the changes in allelic
burden of the compound heterozygous JAK1 mutation suggest tumor immunoediting driv-
en by selection of the JAK1 variant as the basis of immunotherapy resistance, the studies
here do not causally implicate the alteration for the clinical phenotype. Second, WES of
pre- and post-treatment core needle tumor biopsies from the liver lesion may not capture
the biological characteristics of widespread metastatic cancer involving mediastinal lymph
nodes, pleura, and adrenals. This limitation may partly be offset by profiling of ctDNA atmul-
tiple time points.We observed amoderate level of concordance between ctDNA and tumor,
withmost of the tumor variants detected in ctDNA (368 variants were shared including 69.4%
of tumor variants and 41.4% of ctDNA variants; Supplemental Fig. S10). Further, consistent
with the notion of ctDNA providing a global view representing genomic changes from
diverse metastatic sites (Moreno et al. 2019), ctDNA also captured variants that were not de-
tected in the tumor (58.6% of ctDNA variants were unique to ctDNA; n=521). Third, the tu-
mor transcriptome data generally supported reduced post-treatment JAK1 signaling, with
the notable exception of STAT1 expression, which increased post-treatment (Fig. 3D).
Several cell-intrinsic pathways activate STAT1 independently of interferons (Ramsauer
et al. 2002; Dempoya et al. 2012; Luu et al. 2014; Collins-McMillen et al. 2017), including
Figure 4. Schema of JAK1 function impacting mutations leading to immunotherapy resistance. (JAK) Janus
kinase, (PD-L1) programmed death-ligand 1, (PARPi) Poly (ADP-ribose) polymerase inhibition, (dMMR) mis-
match repair deficiency, (IO) immune checkpoint blockade, (mt) mutant, (TILs) tumor infiltrating lymphocytes,
(ISGs) interferon stimulated genes.
Genomic and immune responses in IO-resistant dMMR
C O L D S P R I N G H A R B O R
Molecular Case Studies
Takahashi et al. 2020 Cold Spring Harb Mol Case Stud 6: a005678 8 of 12
 
the cGAS-STING pathway (Kreienkamp et al. 2018) up-regulated by PARP inhibition (Sen
et al. 2019), and may have contributed to the isolated STAT1 up-regulation. Finally, the im-
pact of dMMR on pathogenesis, prognosis, and patterns of response and resistance to anti-
cancer therapies in SCLC is not defined, in contrast to colorectal or endometrial carcinomas,
which are often considered as “proof of principle” of the dMMR paradigm. Thus, the puta-
tive resistance mechanism identified here in a dMMR SCLC patient needs validation in the
setting of these more typical dMMR tumors.
In conclusion, we describe a patient with dMMR tumor resistant to immune checkpoint
blockade despite exhibiting molecular features of dMMR tumors. Functional characteriza-
tion and allelic burden tracking of the compound heterozygous JAK1mutation suggests tu-
mor immunoediting driven by selection of the JAK1 variant may underlie immune escape.




The patient was enrolled in a single-arm phase II study (NCT02484404) and was treated
with PD-L1 inhibitor durvalumab (1500 mg administered every 4 wk) and PARP inhibitor ola-
parib (300 mg administered twice daily) (Thomas et al. 2019). Written informed consent was
obtained from the patient. Tumor response was assessed using Response Evaluation Criteria
in Solid Tumors (RECIST v 1.1). The study was approved by the Office for Human Research
Protections at the Department of Health and Human Services.
Tumor, Germline, and ctDNA Sequencing
DNA and RNAwere sequenced from formalin-fixed, paraffin-embedded (FFPE) tumor tissue
samples using WES and RNA-seq, and whole-exome sequenced from ctDNA, and PBMCs
for germline control. Detailed methods of sequencing and analyses are provided in the
Supplemental Methods.
Immunohistochemistry
Five-micron sections of FFPE tissue were assessed for PD-L1 expression, TILs, JAK1, and
phosphorylated JAK1 protein expression using the following antibodies and detection
methods following the manufacturer’s protocol: PD-L1 (1:3 dilution, clone SP142 [Springer
Biosciences], Leica Bond [Leica Biosystems]), CD3 (predilute, clone 2GV6, Ventana and
Ventana BenchMark Ultra [Ventana Medical Systems]), and CD8 (1:25, clone CD8/144B
[Dako], Ventana BenchMark Ultra [Ventana Medical Systems]), JAK1 (1:500), and phosphor-
ylated JAK1Tyr1034/1035 (1:100) (Cell Signaling Technologies Inc.).
Plasma Cytokine Analyses
Plasma cytokine levels were measured pretreatment, 2 and 8 wk after treatment using the
Meso-Scale Discovery (MSD) Human Biomarker Group 1 U-Plex and Human TGF-beta
Combo kits. Initially 74 cytokines were measured and 18 cytokines (IFN-γ, IL-8, IL-9, IL-10,
IL-13, CXCL10, I-TAC, IL-21, IL-29/IFN-λ1, MCP-2, MCP-3, MCP-4, MIP-1α, MIP-1β, FLT3L,
IL-1RA, MIF, M-CSF) were finally analyzed after quality control.
PBMC Immune Subset Analysis
Blood samples were collected in an 8-mL sodium citrate CPT tube (BD) pretreatment, 2 wk,
and 8wk after treatment. PBMCs were isolated and analyzed as previously described (Tomita
Genomic and immune responses in IO-resistant dMMR
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et al. 2016). Flow cytometric analyses were performed using a MACSQuant Analyzer
(Miltenyi Biotec). Data were analyzed using FlowJo software (FlowJo, LLC) (Ziegler-
Heitbrock et al. 2010; Zawada et al. 2011). Please refer to Supplemental Methods for
more details of methods.
ADDITIONAL INFORMATION
Data Deposition and Access
Raw WES and RNA-seq data are deposited in the database of Genotypes and Phenotypes
(dbGaP) (https://www.ncbi.nlm.nih.gov/gap/) under accession number phs002089.v1.p1.
The JAK1 variants were submitted to COSMIC (https://cancer.sanger.ac.uk/cosmic) and
can be found using COSMIC identifier COSP48518.
Ethics Statement
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